Journal
SCIENCE
Volume 358, Issue 6360, Pages 218-222Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.aan7969
Keywords
-
Categories
Funding
- American Cancer Society Postdoctoral Fellowship [PF-15-007-01-CDD]
- NSF Graduate Research Fellowships
- NSF [ECCS-1542152]
- NIH [P30 CA124435, R01CA031845, AI124743]
Ask authors/readers for more resources
Bryostatin 1 is an exceedingly scarce marine-derived natural product that is in clinical development directed at HIV/AIDS eradication, cancer immunotherapy, and the treatment of Alzheimer's disease. Despite this unique portfolio of indications, its availability has been limited and variable, thus impeding research and clinical studies. Here, we report a total synthesis of bryostatin 1 that proceeds in 29 total steps (19 in the longest linear sequence, >80% average yield per step), collectively produces grams of material, and can be scaled to meet clinical needs (similar to 20 grams per year). This practical solution to the bryostatin supply problem also opens broad, facile, and efficient access to derivatives and potentially superior analogs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available